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This document summarizes the rationale, equipment, protocol, assays, internal quality control, data 
cleaning, external quality control, and procedures for the measurement and classification of glucose 
homeostasis at the Wave V home exam. Whenever possible, data collection and methods in Wave V 
mirrored those of Wave IV to ensure comparability of data between waves, although important inter-
Wave differences exist and are grey-highlighted herein. This document is one in a set of Wave V user 
guides. User guides are also available to describe protocols for the following biological measures at 
Wave V: 
 Anthropometrics 
 Cardiovascular Measures 
 Medication Use – Home Exam 
 Baroreflex Sensitivity & Hemodynamic Recovery 
 Inflammation and Immune Function 
 Lipids 




This research uses data from Add Health, a program project directed by Kathleen Mullan Harris and 
designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North 
Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development, with cooperative funding from 23 other federal 
agencies and foundations. We gratefully acknowledge Carolyn Halpern, Nancy Dole, Joyce Tabor, and 
Sarah Dean for their dedication to the quality of the Add Health data in this document. Information on 
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1. Introduction 
Wave IV measures of glucose homeostasis were based on dried blood spots collected using capillary 
finger prick.1 In contrast, Wave V measures of glucose homeostasis were based on venous blood 
collected via phlebotomy. The blood was collected by field examiners (FEs) certified in phlebotomy, 
chilled at 4°C during the remainder of the home exam, centrifuged immediately afterward, aliquoted 
into transport tubes, and then sent overnight to a laboratory for assay. 
 
Assayed Glucose Concentrations 
 
• Glucose (mg/dl) 
• Hemoglobin A1c (HbA1c, %) 
 
Moreover, the restricted use Add Health Wave V data include six constructed measures: 
 
• Fasting status (h) 
• Classification of fasting glucose2  
• Classification of non-fasting glucose2 
• Classification of HbA1c 2 
• Anti-diabetic medication use 
• Joint classification of glucose, HbA1c, self-reported history of diabetes, and anti-diabetic 
medication use 
 
2. General Overview of Data Collection 
All Wave V venous blood samples were collected during home exams performed by FEs from two Add 
Health data collection partners: Examination Management Services, Inc. (2016–2017) and Hooper 
Holmes, Inc. (2018–2019). All FEs were trained and certified using a custom program specific to the Add 
Health protocol. FEs used a 7” Samsung Galaxy Tab 4 tablet to record and transmit data. An Add Health 
data collection application (Open Data Kit or ODK) installed on the tablet guided the FEs through the 
home exam protocol. In addition, FEs received a series of job aids, both on paper and on the tablet, to 
serve as quick reference guides when completing the protocol. Each tablet also contained an in-depth 
Add Health training manual that could be accessed at any time. 
 
FEs conducted home exams among previously consented respondents. All FEs were phlebotomy-
certified and had at least two years of experience collecting venous blood. Before home exams, FEs 
were sent a Visit Supply Kit that included a box for shipping blood to the lab and a Blood Collection Kit 
containing most required materials for the blood collection. FEs supplied additional materials, as needed 
(see section 3.2). Protocols for blood collection were dictated to FEs by the handheld 7” Samsung tablet 
used during all home exams. The tablet gave step-by-step directions for the blood collection and 
required FEs to enter information about the blood draw for each respondent. All respondents had the 
option to decline part or all the blood draw, although declining did not affect their ability to participate 
in the rest of the home exam.  Overall, 91.8% of the respondents agreed to and completed the blood 
draw.  Of the remainder, 6.5% refused, 1.3% agreed but the blood draw was unsuccessful, and < 1% had 
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exams terminated before the blood draw (see the blood draw status variable H5BLOOD in the bdemo5 
data set and codebook).   
 
Blood collection was the last step in the home exam. Afterwards, all collection tubes were inverted 8-10 
times to distribute the blood and contents of the tubes and then chilled at 4⁰ C (on ice or frozen cold 
packs) for up to two hours. Subsequent processing involved centrifuging specific tubes then aliquoting 
serum and plasma into color-coded transport tubes pre-labelled with unique barcode identifiers linking 
the blood to a particular respondent. Then the transport tubes were packaged in a Styrofoam Box with 
frozen cold packs and shipped overnight via FedEx to the Laboratory for Clinical Biochemistry Research 
(LCBR) at the University of Vermont. Overnight shipment enabled receipt by LCBR before 10:30 am the 
next morning.  Upon receipt, LCBR documented the arrival of the transport tubes, evaluated their 
condition, processed them, and either assayed the specimens or aliquoted and archived them in -80°C 
freezers.   
 
3. Blood Collection 
3.1 Rationale 
 
Venous blood was collected to provide Add Health with the biological specimens necessary to assay and 
interpret a pre-specified panel of metabolic, hematologic, inflammatory, immune, and renal biomarkers, 
including the measures of glucose homeostasis described herein. It also was collected to establish an 





Before exams, FEs were shipped a Visit Supply Kit (Exhibit 1) including (1) a cardboard Shipping Box with 
an inner Styrofoam Box and two cold packs for shipping collected samples to LCBR, (2) a large Tyvek 
envelope in which to ship the Shipping Box, and (3) a Blood Collection Kit for collecting blood.  The Blood 
Collection Kit contained: 
 
• Biohazard-labelled Ziploc bag 
• Latex-free gloves 
• 2”x2” gauze 
• Latex-free, Band-Aid type adhesive dressings 
• Latex-free, strap tourniquet 
• Alcohol prep pads, disposable pipets 
• Single-use vacutainer (blood collection) tube holder 
• 21-gauge Eclipse straight needle 
• 21-gauge butterfly needle 
• (3) disposable 3 ml graduated transfer pipets 
• (2) 8.5 ml serum separation transport (SST) vacutainer tubes 
• (1) 6 ml sodium fluoride/potassium oxalate (NaFl/KOx)-containing vacutainer tube, if needed for 
the glucose sub-study (see Section 4.1.2.1) 
• (1) 3- or 4- ml potassium ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tube 
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• (1) 10 ml EDTA-containing vacutainer tube 
• (1) 10 ml PAXgene vacutainer tube (containing 7.5 ml of preservative) 
• (4) 10 ml transport tubes with color coded caps  
• Extra barcode labels 
 
BD Biosciences (San Jose, CA) supplied all the vacutainer and transport tubes. As of February 2018, their 
3 ml EDTA vacutainer tube (Cat #367835) was no longer available, so Add Health switched to the 4 ml 




Exhibit 1. Visit Supply and Blood Collection Kits 
 
FEs were responsible for providing ancillary materials for each home exam, including but not limited to a 
chux-type absorbent under pad, a sharps container, and a cooler with cold packs for keeping samples 
cold before packaging and shipping them to LCBR. 
 
3.3 General Protocol 
 
3.3.1 Blood Collection 
 
The blood draw was performed as the final stage of the home exam following collection of 
anthropometric, cardiovascular, and medication information. After confirming respondents were 
comfortable giving blood, respondents were asked to either sit or recline at their discretion. They also 
were asked if they had problems in the past with blood collection such as fainting, bleeding, or hard-to-
find veins. FEs were instructed to ensure the blood collection area was private, uncluttered, and fully 
prepared before beginning the blood draw. Preparation involved placing the chux pad, organizing the 
vacutainer tubes/supplies, preparing the cooler to accept the blood samples, and scanning the barcode 
located on the outside of the Blood Collection Kit. Scanning it automatically captured a unique, eight-
digit code, thereby linking the respondent to the transport tubes / labels within it, the corresponding 
ODK questionnaire data, and ultimately to LCBR results. 
 
Following standard phlebotomy protocols, FEs asked respondents to identify an arm for collecting blood, 
applied the tourniquet to that arm, and identified a vein in the antecubital fossa for venipuncture. If no 
vein appeared suitable, FEs asked to try the opposite arm. Unless respondents had objections, 
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venipuncture was performed on the best potential vein and whole blood was collected, as summarized 
below: 
 
• Put on nitrile gloves. 
• Have the respondent extend his/her arm on the protective pad, palm up and straight at the 
elbow. 
• Inspect the arm. Do not draw blood from an arm that has a rash, open sore, is swollen or shows 
signs of a recent venipuncture or hematoma. Do not draw blood from an arm that contains an 
arterial access such as a fistula or shunt.  
• Apply the tourniquet several inches above the elbow and palpate for a suitable vein.  
• Select a vein that is palpable and well-fixed to surrounding tissue. 
• Open the needle assembly unit and attach it to the vacutainer holder.  
• Ask the respondent to make a tight fist. Cleanse the area with an alcohol wipe using a circular 
motion and allow the area to air dry. 
• Remove the cover from the needle. 
• The vein should be fixed or held taut during the puncture. Push the needle firmly and 
deliberately into the vein. When firmly in the vein, blood appears in the tubing of the needle 
assembly past the end of the needle. 
• Quickly push the first vacutainer tube (using the sequence in the table above) onto the needle in 
the holder, puncturing the center of the stopper.  
• Release the tourniquet after the flow is established or if the respondent becomes 
uncomfortable. The respondent may open his/her fist once blood flow is established. 
• When the first vacutainer tube is filled to capacity, remove it from the holder and place the next 
vacutainer tube in the holder. 
• Gently invert each vacutainer tube 8-10 times immediately upon removing each one and while 
filling the next one. Repeat until all the desired vacutainer tubes are filled. 
• Place all filled vacutainer tubes directly into a cooler with ice or ice packs. 
• When the last vacutainer tube is filled, remove the tourniquet, carefully withdraw the needle, 
and cover the venipuncture site with a sterile gauze pad. 
• Never apply pressure to the gauze until the needle is clear of the puncture site and away from 
the arm. 
• Have the respondent hold the gauze pad with mild pressure and sit quietly for a few minutes.  
• Slide the needle safety guard forward to prevent an accidental needle stick. Discard the entire 
used needle assembly in a sharps container.  
• Check the venipuncture site. If it is adequately clotted, remove the gauze and apply a bandage. 
If after a few minutes, bleeding continues keep direct pressure on the site for 5 minutes. 
• Encourage the respondent to sit quietly for a few minutes. Due to a fasting blood draw 
encourage the respondent to eat a snack if needed. 
 
When the first attempt at blood collection was unsuccessful, FEs were allowed to ask to draw blood 
from the opposite arm. However, no more than two blood collection attempts were permitted. 
Moreover, only the antecubital fossa was acceptable for blood draw. FEs were not allowed to collect 
blood from any other sites, such as the back of the hand. 
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Either 5 or 6 tubes of blood were collected per respondent, depending on eligibility for a separate 
glucose sub-study (see Section 4.1.2.1). Collection order, tube type, and processing information are 
listed below (Exhibit 2). 
 






1 8.5 ml SST Yes Serum Discarded 
Assays: glucose, total 
cholesterol, high- & low- 
density lipoprotein-
cholesterol, triglycerides, 
high sensitivity C reactive 
protein, creatinine & 
cystatin C 
2 10 ml EDTA Yes Plasma 
RBC/buffy 
coat 
Archival: for future use 
3 
3 or 4 ml 
EDTA 
No N/A N/A 
Assay: hemoglobin A1c 
Archival: for future use 








No N/A N/A Archival: for future use 
 
Exhibit 2. Tubes of Blood Collected 
   
3.3.2 Blood Processing 
 
The venous blood draw concluded the home exam. After cleaning up all supplies and equipment, FEs left 
the exam sites and were allowed a maximum of two hours before processing the blood which was 
chilled at 4⁰ C (on ice or frozen cold packs) in the interim. 
 
All FEs centrifuged specific blood collection tubes, including the 8.5 ml SST, 10 ml EDTA, and when 
collected, the 6 ml NaFl/KOx vacutainer tubes. The 3-4 ml EDTA vacutainer tube used for the HbA1c 
assay was not centrifuged. FEs centrifuged tubes for ≥ 10 min at ≥ 1300 g, depending on the capabilities 
of their centrifuge. After centrifugation, FEs used the graduated transfer pipettes included in the Blood 
Collection Kit to aliquot serum from the SST and (separately, when collected) plasma from the NaFl/KOx 
vacutainer tubes into 10 ml, round bottom, skirted transport tubes (BD Biosciences, NJ). FEs aliquoted as 
much supernatant as possible into the transport tubes but avoided disturbing the precipitate layer. A 
red cap identified transport tubes containing serum from the SST vacutainer tubes, a blue cap identified 
transport tubes containing plasma from the 10 ml EDTA vacutainer tube, and a white cap identified the 
transport tube containing plasma from the Na/Fl/KOx tube. Transport tubes were chilled at 4⁰ C (on ice 
or frozen cold packs) until packaged for shipment to LCBR. Exhibit 3 demonstrates the complete blood 
processing protocol. 
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Exhibit 3. Blood Processing Protocol 
 
After processing the blood, FEs took a loose barcode label provided in the Blood Collection Kit and 
affixed it to a paper manifest designed to accompany the transport tubes to LCBR. The loose barcode 
label matched the barcode labels on the transport tubes and the Shipping Box. FEs recorded all 
vacutainer tubes that were collected and identified all difficulties during blood draw or processing on 
the manifest as well as in the tablet. The barcode-labelled manifest was designed to be scanned on 
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3.3.3 Shipment of Samples 
 
Immediately before shipment, FEs removed two cold packs from the freezer, sandwiched the transport 
tubes between them, enclosed the sandwich within the Styrofoam Box, placed the manifest on top of 
the Styrofoam Box, sealed the cardboard Shipping Box around it, put the cardboard Shipping Box inside 
the Tyvek envelope, applied a pre-printed FedEx shipping label to the envelope, carried it to a FedEx 
office, and handed it to a FedEx representative (in person) for Priority Overnight shipment to LCBR with 
arrival the following morning.  FEs were not permitted to leave shipments at unattended FedEx drop 
boxes.  
 
When overnight shipment was impossible, FEs noted this on the manifest and held unboxed transport 
tubes in a refrigerator approved for biological specimens or cooler with enough cold packs to keep them 
chilled at 4⁰ C overnight without risk of freezing (or thawing), as is possible on wet or dry ice. The 
transport tubes were packaged and shipped the next day using freshly frozen cold packs. 
 
3.3.4 Receipt of Samples at LCBR 
 
LCBR technicians specifically trained for Add Health Wave V received and immediately processed 
samples each morning. They unpacked the shipping boxes one at a time, evaluated the volume and 
quality of each transport tube, and entered them into a custom-made laboratory information 
management system (LIMS) program. 
 
After re-centrifuging the serum samples for glucose assays at 4° C for 10 min at 30,000 g, the technicians 
aspirated the supernatant, discarded all remaining precipitate, transferred the aspirate to pre-labelled 
tubes, and placed them in a biospecimen refrigerator for archival (in 1 ml aliquots at -80° C) or assay 
(500 ul aliquot). The LCBR technicians entered all aliquot information into the LIMS system. 
 
The LCBR technicians also remixed the vacutainer tube used to collect and transport the venous whole 
blood sample for HbA1c assay, then aspirated and archived a 1 ml aliquot for future use. 350 μl of the 
remaining sample was then transferred to a pre-labelled tube for a 5-10-minute cold transport via a 
daily 3:00 pm courier to Pathology and Laboratory Medicine, in the University of Vermont Medical 
Center (UVMMC) for analysis. 
 
 
4. Assay and Internal Quality Control 




Serum glucose was assayed because of its central role in the identification of impaired fasting glucose / 
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4.1.2 Colorimetric Assay Protocol 
 
All glucose assays were run on the same day of sample arrival at LCBR using an Ortho VITROS 5600 
Integrated System (Ortho Clinical Diagnostics, Raritan, NJ) and VITROS Chemistry Products GLU slides, 
i.e. multilayered, analytical elements coated on polyester supports (see Exhibit 4). Serum from venous 
blood collected using the SST vacutainer tubes was introduced into the VITROS system by placing sample 
vials holding 500 µl of serum into an automatic sampling tray, after which all processes were 
automatically performed and results output by the VITROS system.  
 
The VITROS system read barcodes on the vials to automatically determine which assays to run. In 
addition to glucose, other assays were run from the same serum sample, including total cholesterol, 
high-density lipoprotein cholesterol, triglycerides, and creatinine. Only the glucose assay is described 




Exhibit 4. Ortho-Vitros GLU slide 
 
Upon introduction of each vial into the analyzer, 10 µl of serum was aspirated, deposited onto a GLU 
slide for analysis, and evenly distributed by the slide’s spreading layer to the underlying layers. The 
oxidation of serum glucose was catalyzed by glucose oxidase to form hydrogen peroxide and gluconate.  
This reaction was followed by an oxidative coupling catalyzed by peroxidase in the presence of dye 
precursors to produce a dye3.   The specific reaction scheme is displayed in Exhibit 5.4 
 
Exhibit 5. Glucose Assay Reaction Scheme 
The intensity of the dye was measured and corresponding glucose concentration inferred at room 
temperature by comparing reflected light output at 540 nm to a standard curve generated using a 
VITROS Chemistry Products Calibrator Kit (Ortho Clinical Diagnostics, Raritan, NJ).5 The concentrations 
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were output to a Sunquest computer system (Sunquest Information Systems, Tucson AZ) that linked the 
UVMMC data with LCBR’s LIMS system. 
 
The VITROS 5600 system’s dynamic reporting range of the glucose assay was 20-625 mg/dl. When 
concentrations exceeded the upper limit, the VITROS system automatically diluted the samples 1:2 with 
a VITROS Chemistry Products FS Diluent Pack (Ortho Clinical Diagnostics, Raritan, NJ) until the 
concentrations were within range. Dilutions and glucose concentrations that accounted for the reflexive 
dilutions via multiplication by the dilution factor were reported simultaneously.  The final glucose 
concentrations (H5GLUCOS) ranged from 40 to 618 mg/dL. 
 
4.1.2.1 Glucose Sub Study Assay Protocol 
 
From a stratified random sample of 102 respondents (see Section 5.2), venous blood also was collected 
using NaFl/KOx vacutainer tubes (Section 3.2). Although SST vacutainer tubes yield serum and NaFl/KOx 
vacutainer tubes yield plasma, assay procedures based on blood collected using both types of vacutainer 
tubes were identical. 
 
4.1.3 Internal Quality Control 
 
The Ortho-VITROS system was maintained daily by cleaning machine components, replacing all reagents, 
and running known quality control samples (Ortho Clinical Diagnostics, Raritan, NJ). Internal quality 
controls consisted of VITROS Performance Verifier I, which was typically 70-80 mg/dl glucose, and 
VITROS Performance Verifier II, which was typically 260-300 mg/dl glucose, depending on the specific lot 
used.  
 
Values assigned to the VITROS Chemistry Products Calibrator Kit for glucose are traceable to the 
Certified NIST (National Institute of Standards and Technology) Reference Material, SRM® (Standard 
Reference Material) 917. The Ortho-Clinical Diagnostics calibration laboratory uses SRM® 917 to 
calibrate the CDC Hexokinase method to support glucose concentration assignment for VITROS 
Calibrator Kit 1. 
 
In addition to the daily quality control, LCBR used two pools of samples from twenty normal donors (US 
Biologicals, Salem, MA) in longitudinal quality control analyses. One pool was an EDTA plasma normal 
donor pool (Lot #E050115). The other pool was a serum normal donor pool (Lot #S042715).  LCBR 
periodically assayed both pools over the course of Wave V. The plasma and serum glucose 
concentration mean (coefficient of variation) based on those assays was 98 mg/dl (0.86%) and 116 
mg/dl (0.72%), respectively. When glucose concentrations exceeded acceptable parameters, the Ortho-
VITROS system was investigated and repaired.  
 




HbA1c was assayed in venous whole blood because it is an integrated measure of glucose homeostasis, 
reflecting average blood glucose over the preceding two to three months. The measure plays a critical 
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role in the management of diabetes since it is correlated with micro- and macrovascular complications 
and is widely used as the standard biomarker for the adequacy of glycemic management.2 
 
4.2.2 Colorimetric Assay Protocol 
 
HbA1c assays were run by LCBR twice weekly on Tuesdays and Thursdays. Samples received at LCBR 
were stored at 4°C in sample refrigerators until assay day, when they were delivered to UVMMC with all 
other samples for that day. Assays were performed using the VITROS Chemistry Products HbA1c 
Reagent Kit (Ortho Clinical Diagnostics, Raritan, NJ) in conjunction with the VITROS Chemistry Products 
Calibrator Kit 31 (Ortho Clinical Diagnostics, Raritan, NJ) on the VITROS 5600 Integrated System. The 
VITROS Chemistry Products HbA1c Reagents are two dual-chambered packages containing ready-to-use 
liquid reagents. The concentrations of total hemoglobin (Hb) and HbA1c were measured in hemolyzed 
samples (see below), controls and calibrators. A new calibrator kit was used each time the reagent lot 
was changed. 
 
350 µl of whole blood was placed into an automatic sampling tray, automatically aspirated, and 
hemolyzed in the VITROS 5600 Integrated System. Calibrators, controls and hemolyzed whole blood 
samples were mixed with Reagent 1 containing an anti-HbA1c antibody to form a soluble antigen-
antibody complex. Hemoglobin in the hemolyzed whole blood was converted with Reagent 1 to a 
hematin derivative that was measured bichromatically at 340 nm and 700 nm. Unbound anti-HbA1c 
antibody reacted with polyhapten (hexapeptide-glycan, A1c Reagent 2) to form an insoluble antibody-
polyhapten immune complex, which was measured turbidimetrically at 340 nm. After a calibration was 
performed for each reagent lot, the HbA1c and total hemoglobin concentrations in each sample were 
determined using the stored calibration curves and the measured absorbance obtained in the assay of 
the hemolyzed sample6. The reaction scheme for this assay is displayed in Exhibit 6. 
 
 
Exhibit 6. HbA1c Assay Reaction Scheme 
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The VITROS 5600 system’s dynamic reporting ranges of the total hemoglobin and HbA1c assays were 
6.0-22.0 g/dL and 0.2-2.5 g/dL, respectively. In contrast to the glucose assay, automatic dilution of 
samples was not available for the HbA1c assay. So, when either the total hemoglobin or HbA1c 
concentration exceeded its respective upper limit, the original samples were resuspended by gentle 
inversion, diluted with an equal volume of saline, and re‑analyzed. However, multiplying by the dilution 
factor was not necessary to estimate the pre-dilution HbA1c (%), because total hemoglobin and HbA1c 
were both diluted. 
 
The assay yielded the quantitative concentrations of HbA1c and total hemoglobin on which HbA1c in 
Système International7 units (mmol/mol) = 1000 x HbA1c (g/dl) / Hb (g/dl) and in National 
Glycohemoglobin Standardization Program7 units (%) = HbA1c (mmol/mol) x 0.09148 + 2.152 were 
computed internally.  The latter percentages (H5HBA1C) ranged from 4.1% to 14.0%. 
  
4.2.3 Internal Quality Control 
 
The Ortho-VITROS system was maintained daily by cleaning machine components, replacing all reagents, 
and running known quality controls samples (Ortho Clinical Diagnostics, Raritan, NJ). Internal quality 
controls consisted of VITROS Chemistry Products %A1c Performance Verifier I, which was typically 40-45 
mmol/mol HbA1c, 6.0-6.2% HbA1c, and VITROS %A1c Performance Verifier II, which was typically 85-
110 mmol/mol HbA1c, 10-13% HbA1c.  
 
The values assigned to the VITROS Chemistry Products Calibrator Kit 31 for HbA1c (%) are traceable to 
the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) Reference Method.8  
 
Calibration parameters were automatically assessed by the VITROS 5600 system against a set of quality 
parameters built into the machine. Failure to meet any of the predefined quality parameters results in a 
failed calibration. The calibration report was used in conjunction with quality control results to 
determine the validity of a calibration. 
 




Within a race/ethnicity- and sex-stratified random sample of 103 Add Health respondents (81% fasting ≥ 
8 hours) among whom venous blood was collected twice, on average 14.3 (95% confidence interval: 
13.0–15.5) days apart, typically by the same FE and at approximately the same time of day, the reliability 
of glucose (mg/dl) and HbA1c (%) was estimated as an intra-class correlation coefficient (ICC, 95% 
confidence interval) [Exhibit 7].  The estimates suggest that the home exam venous blood collected at 
Add Health Wave V yields a comparably reliable measure of HbA1c and much more reliable measure of 
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Measure N ICC 95% CI 
Glucose (mg/dl)  103 0.94 (0.91, 0.96) 
HbA1c (%) 101 0.99 (0.99, 0.99) 
 








5.2 Validity  
 
Within a race/ethnicity-, sex-, and Wave IV HbA1c-stratified random sample of 102 Wave V Add Health 
respondents (fasting ≥ 8 hour: 64%; range of collect-assay interval: 1-4 days), venous blood was 
collected using both the SST and NaFl/KOx vacutainer tubes introduced in Sections 3.2 and 4.1.2.1.  
HbA1c strata were defined as < 5.7% (normal), 5.7-6.4% (pre-diabetic), and ≥ 6.5% (diabetic) to 
represent the anticipated range of glucose homeostasis at Wave V.2  The sodium fluoride in NaFl/KOx 
vacutainer tubes chemically inhibited cellular glycolysis during processing/shipping, while the serum 
separator gel in SST vacutainer tubes physically inhibited it by liquifying on contact with blood, 
migrating, and then forming a serum-cell barrier.9,10 Mean (95% confidence interval) glucose was only 
1.2 (0.1-2.2) mg/dl higher in blood collected using the SST vacutainer tubes than in blood collected using 
the NaFl/KOx vacutainer tubes.  Moreover, in a Deming regression model of SST on NaFl/KOx glucose 
concentrations, the intercept and slope (95% confidence intervals) were no different from 0 and 1 
[Exhibit 8].11,12 The estimates suggest that over a wide range of glucose concentrations in blood collected 
using the SST vacutainer tubes, assayed values are unlikely to be spuriously decreased due to pre-
analytical delays in assaying samples.  
 
- Line of Identity — Deming Regression 




















Exhibit 8. Scatter Plot of Glucose 
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6. Constructed Variables 
 
6.1 Fasting Status [H5FASTTM] 
 
During the home exam before blood was collected, all respondents were asked the following question: 
“At what time did you last eat or drink anything other than water, including sugar-containing candy or 
gum?” Responses to the question were recorded in hours and minutes and designated AM or PM. All 
respondents were then asked, “Was that today or yesterday?” To calculate fasting times, responses to 
the above question were subtracted from the tablet start-of-blood collection date/time stamp. Data on 
fasting times outside the 0-23.9-hour range were recoded to missing among 60 respondents. Values that 
were deemed implausible (≥ 24 hours) were assigned a code of 999, while negative values that were due 
to unrealistic computer date/time stamps were assigned a code of -999. 
 
6.2 Fasted for Eight Hours or More [H5FASTGL] 
 
Respondents who were fasting (≥ 8 hours) and non-fasting (< 8 hours) at the time of blood collection 
were identified (1,0). 
 
6.3 Classification of Fasting Glucose [H5CFGLU] 
 
The classification of glucose concentrations among Add Health respondents who were fasting (≥ 8 
hours) at the time of blood collection was constructed based on the 2020 American Diabetes Association 
clinical practice recommendations for the diagnosis and classification of diabetes.2 Three classes of 







1 ≤ 99 Normal 
2 100 - 125 Impaired Fasting Glucose (IFG) / Pre-Diabetes 
3 ≥ 126 Diabetes 
  
Exhibit 9. Classification of Fasting Glucose 
 
6.4 Classification of Non-Fasting Glucose [H5CNFGLU] 
 
The classification of glucose concentrations among Add Health respondents who were non- fasting (< 8 
hours) at the time of blood collection was constructed based on the 2020 American Diabetes Association 
clinical practice recommendations for the diagnosis and classification of diabetes.2 Two classes of non-
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1 < 200 Normal 
2 ≥ 200 Diabetes 
 




6.5 Classification of HbA1c [H5CHBA1C] 
 
The classification of HbA1c among Add Health respondents was constructed without regard to fasting 
status at the time of blood collection based on the 2020 American Diabetes Association clinical practice 
recommendations for the diagnosis and classification of diabetes.2 Three classes of HbA1c are defined in 
Exhibit 11: 
 
Classification HbA1c (%) ADA Class 
1 < 5.7 Normal 
2 5.7 - 6.4 Pre-Diabetes 
3 ≥ 6.5 Diabetes 
 
Exhibit 11. Classification of HbA1c 
  
6.6 Anti-diabetic Medication Use [H5C_MED] 
 
Use of a prescription medication in the past four weeks in one or more of the therapeutic classes listed 
in Exhibit 12 was assigned a value of 1.  Non-use of a prescription medication in the past four weeks in 
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Class Label Variable 
358-099-***  Antidiabetic agents 
H5C_MED 
358-099-213  Sulfonylureas 
358-099-214  Non-sulfonylureas 
358-099-215  Insulin 
358-099-216  Alpha-glucosidase inhibitors 
358-099-271  Thiazolidinediones   
358-099-282  Meglitinides   
358-099-309  Miscellaneous antidiabetic agents   
358-099-314  Antidiabetic combinations   
358-099-371  Dipeptidyl peptidase 4 inhibitors  
358-099-372  Amylin analogs  
358-099-373  Incretin mimetics  
358-099-458  SGLT-2 inhibitors 
 
Exhibit 12. Anti-diabetic Medications 
 
Therapeutically classified use of prescription medication in particular classes may confound biomarker-
based estimates of disease prevalence or risk. For example, use of antidiabetic medications may 
confound glucose or HbA1c-based estimates of diabetes prevalence or cardiovascular disease risk. 
However, the (1,0) classifications should be used cautiously in the investigation or control of potential 
confounding, because selection biases often threaten the study of non-randomized medication 
exposures. 
 
6.7 Joint Classification of Diabetes [H5DIABJC] 
 
Respondents were flagged as having evidence of diabetes if they met at least one of the following 













7. The Glucose Homeostasis Data File (bglua1c5.xpt) 
7.1. Structure 
Criterion (≥ 1 of the following must be true) Variable & Value 
Fasting glucose ≥ 126 mg/dl H5CFGLU = 3 
Non-fasting glucose ≥ 200 mg/dl H5CNFGLU = 2 
HbA1c ≥ 6.5% H5CHBA1C = 3 
Self-reported history of diabetes except during pregnancy H5Q045B = 1 
Anti-diabetic medication-use in the past 4 weeks H5C_MED = 1 
 
Exhibit 13. Criteria Used to Identify Diabetes 
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The structure of the disseminated glucose homeostasis data file is flat.  This means that it is a 
respondent-level data file, where each respondent has one and only one record.  The respondent’s 




The glucose homeostasis data file includes the variables below, which are described in the 




Despite attempts to harmonize methods across Waves IV and V, important inter-Wave differences in 
protocols, biospecimens, assays, and data quality exist, as grey-highlighted here and above.  Their 
existence suggests that the measures of glucose homeostasis described in Sections 1-6 may not be 
readily comparable from wave to wave.  Caution should therefore be exercised when leveraging 
repeated measures of glucose homeostasis from Wave IV-V, whether they are primary measures or 
constructed classifications.  Indeed, the merit of pre-analytical z-transformation or quantile-based 
classification of Wave IV-V biomarkers (glucose; HbA1c) and the potential pitfall otherwise associated 
with equating values in their original units (mg/dl; %) across visits should be carefully considered before 
using these data. 
 
  
Variable Name Variable Description 
AID Respondent Identifier 
H5GLUCOS   Glucose (mg/dl) 
H5HBA1C    Hemoglobin A1c (HbA1c, %) 
H5FASTTM  Hours since last ate 
H5CFGLU   Classification of fasting glucose 
H5CNFGLU    Classification of non-fasting glucose 
H5CHBA1C  Classification of HbA1c 
H5Q045B Q045b Ever diagnosed with diabetes 
H5C_MED Flag: Anti-diabetic medication use 
H5DIABJC Diabetes joint classification  
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